Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis

Cirrhosis Clinical Trial

— CIRROXABAN  

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02643212
• Other study ID #: 2014-005523-27
• Status: Recruiting
• Phase: Phase 3
• First received: October 26, 2015
• Last updated: April 24, 2018
• Start date: May 2016
• Est. completion date: December 2019

Study information

• Verified date: April 2018
• Source: Hospital Clinic of Barcelona
• Contact: Juan Carlos García Pagan, MD
• Phone: +34 93 227 54 00
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the study will determine if patients with liver cirrhosis, anticoagulation free survival improves hypertension decompensation portal and / or transplantation without serious side effects. For it is conduct a double-blind multicenter clinical trial in which patients will be randomized to receive Rivaroxaban or placebo. It included 160 patients with liver cirrhosis and insufficiency mild to moderate hepatic. It will also analyze and develop secondary endpoint portal vein thrombosis. The confirmation of our hypothesis would lead to a radical change in treatment of patients with cirrhosis include treatment with Rivaroxaban in its drove.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Aged between 18 and 75 years of both sexes.

• Clinical and / or laboratory criteria, ultrasound and / or liver biopsy compatible with the diagnosis of viral cirrhosis (If hepatitis B virus: hepatitis B virus-DNA must be negative; if hepatitis C virus: sustained virologic response should be at least for 6 months prior to enrollment); alcohol (in the last 6 months: in men less than 60 g daily intake in women less than 40 g); nonalcoholic steatohepatitis and cryptogenic.

• Presence of clinically significant portal hypertension defined by clinical criteria (presence of esophageal varices or ascites), elastography (liver Fibroscan® ? 21 kPa) or hemodynamic (Hepatic venous pressure gradient > 10 mmHg)

• Mild to moderate hepatic impairment defined by Child-Pugh of 7-10 points.

• Written informed consent to participate in the study

Exclusion Criteria:

• Any previous or current thrombosis in splenoportal axis (must be ruled out by US-Doppler earlier than one month after randomization; if doubts: computed tomography angiography or magnetic resonance angiography if required).

• Background of hepatic encephalopathy grade II or higher

• Ascites that required prior practice of paracentesis in the last year d. Indication for use of anticoagulant and / or antiplatelet therapy for any reason.

• Hypersensitivity to the active ingredient or to excipients

• Active bleeding, clinically significant, or risk of major bleeding.

• Pregnancy and lactation.

• Hepatocellular carcinoma or malignant neoplasia at the time of inclusion.

• Any comorbidity involving a therapeutic limitation and/or a life expectancy <12 months.

• Existence of risk bleeding esophageal varices or prior variceal bleeding. They may not be included until full treatment (stable beta blockers dosage or eradication trough varices ligation).

• Pregnancy or lactation.

• Severe thrombocytopenia <40,000 platelets / dl.

• Kidney failure (creatinine clearance <15ml / min).

• Transjugular intrahepatic portosystemic shunt or portosystemic shunt carrier.

• Child-Pugh score greater than 10.

• In hepatitis C virus liver cirrhosis patients: not carrying at least six months in sustained virologic response. In hepatitis B virus liver cirrhosis patients: hepatitis B virus DNA is not negative .

• Active alcoholism (60 g / day in men and 40 in women)

• Use of potent inhibitors of cytochrome cytochrome P450 3A4 (ketoconazole, protease inhibitor antiretroviral treatment in human immunodeficiency virus patients) or cytochrome inductors (rifampicin. Phenytoin ...).

• Participation in another clinical trial

Related Conditions & MeSH terms

• Cirrhosis
• Fibrosis
• Liver Cirrhosis

Intervention

Drug:
• Rivaroxaban

• Placebo

Locations

Country	Name	City	State
Spain	Hospital German Trias i Pujol	Badalona	Barcelona
Spain	Hospital Clínic i Provincial de Barcelona	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau.	Barcelona
Spain	Hospital Vall d´Hebron	Barcelona
Spain	Hospital Universitari de Bellvitge	Hospitalet de Llobregat	Barcelona
Spain	Hospital Arnau de Vilanova	Lérida
Spain	Hospital Gregorio Marañón	Madrid
Spain	Hospital Ramón y Cajal	Madrid
Spain	Hospital Universitario Puerta de Hierro de Majadahonda	Majadahonda	Madrid
Spain	Hospital Universitario Central de Asturias	Oviedo	Asturias
Spain	Complejo Hospitalario de Pontevedra_Hospital Montecelo	Pontevedra
Spain	Hospital Universitario Marqués de Valdecilla	Santander	Cantabria
Spain	Hospital Universitario Tenerife	Tenerife
Spain	Hospital universitari i politècnic La Fe de Valencia	Valencia

Sponsors (2)

Lead Sponsor	Collaborator
David Garcia Cinca	IDIBAPS - Dr. Juan Carlos García Pagán

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival free of transplant and decompensation / complications of portal hypertension.	Is defined as decompensation / complications of portal hypertension: significant bleeding episode (defined as Baveno V) by portal hypertension (esophageal varices, gastric varices; gastropathy Portal Hypertension); Hepatic encephalopathy grade II or higher.; decompensation of ascites: In patients without ascites decompensation be considered the onset of clinically detectable ascites and confirmed by utrasounds de novo; whereas in those with previous ascites will be considered end-point for worsening ascites if required: a) perform two or more paracentesis evacuator in the next 6 months, or b) the completion of a Transjugular intrahepatic portosystemic shunt.	At month 24
Secondary	Cirrhosis progression disease (bleeding episode, encephalopathy, ascitis)	Bleeding episode due to portal hypertension.; Hepatic encephalopathy grade II or higher.; Ascitic decompensation: In patients without ascites, decompensation defined as "de novo" clinically detectable ascites; whereas in those with previous ascites is considered end-point for worsening ascites if required: a) perform two or more evacuative paracentesis in the following six months, or b) the completion of a TIPS	At month 24
Secondary	Development of portal vein thrombosis detected by ultrasound and confirmed by CT angiography or MRI angiography		At month 24
Secondary	To evaluate the efficacy in preventing complications of portal hypertension	Development of complications of portal hypertension (anamnesis, physical examination, ultrasound and fibrogastroscopy)	At month 24
Secondary	Security of rivaroxaban in patients with liver cirrhosis, number of adverse events and adverse reactions in each arm of study. History and clinical evaluation of bleeding and monitoring of hematocrit. Evaluation of liver function	Evaluate number of bleeding episodes, hematocrit values and number of adverse events and reactions.	At month 24
Secondary	To evaluate the incidence of hepatocellular carcinoma	Incidence of hepatocellular carcinoma by semiannual ultrasound.	At month 24
Secondary	Effect on splenic and liver elasticity measured by fibroscan and / or acoustic radiation force impulse.	Effect of rivaroxaban on liver fibrosis assessed by liver elastography measured by fibroscan and / or acoustic radiation force impulse at baseline and every six months conditions.	At month 24
Secondary	Effect of Rivaroxaban on hepatocellular function estimated by the Child-Pugh and the model for end-stage liver disease scores.		At month 24
Secondary	To correlate levels of anti-factor Xa and Rivaroxaban on survival free of transplant, cirrhosis progression disease (bleeding episode, encephalopathy, ascitis) and number of adverse events and reactions.	To correlate levels of Rivaroxaban and anti-factor Xa to the efficacy and safety of the drug. Rivaroxaban	At month 24
Secondary	To evaluate the effect of Rivaroxaban on hepatic venous pressure gradient	Effect on hepatic venous pressure gradient. Determination of hepatic venous pressure gradient at baseline and 12 months rivaroxaban or placebo	At month 24
Secondary	To assess if Rivaroxaban reduces concentration of intestinal fatty acid binding protein, 16S ribosomal DNA, CD14, interleukin 6, lipopolysaccharide binding protein and lipopolysaccharide	Assess Rivaroxaban reduces bacterial translocation and proinflammatory cytokines. Correlation with clinical events.	At month 24